News for Cytosorbents Corporation (CTSO)

PR NewswirePRINCETON, N.J., May 29, 2025 PRINCETON, N.J., May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment o

CytoSorbents Corporation (CTSO) will present at the Jefferies Global Healthcare Conference on June 5, 2025, in New York. The presentation will be live-s

PR NewswirePRINCETON, N.J., May 22, 2025 Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Pat

CytoSorbents (CTSO) presented new data showing significant reduction in severe bleeding for CABG patients on ticagrelor. Study showed a 67.6% reduction

CytoSorbents Corporation (CTSO) faces a slight decline in Q1 2025 sales but remains stable with constant currency adjustments. Wall Street sets ambitiou

Discover Cytosorbents' Q1 2025 earnings insights, FDA appeal updates for DrugSorb-ATR, German market growth strategies, and their path to breakeven.

Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ETCompany ParticipantsAdanna Alexander - Investor...

PR NewswirePRINCETON, N.J., May 1, 2025 PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purificatio

PR NewswirePRINCETON, N.J., April 29, 2025 PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

CytoSorbents Corporation (CTSO) to announce Q1 2025 financial results on May 14, 2025. The company will host a live conference call and webcast at 4:30

The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulato

PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ( CTSO), a leader in the treatment of life-threatening conditions in the intensive

1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEW

San Francisco confirmed that a child in the city became the first case of H5N1. A panel of biotech leaders discussed what options could be taken next.

Oversubscribed Rights Offering Generated $6.25 Million in Aggregate Gross Proceeds Offering Proceeds Satisfies Debt Covenant, Unlocking $5.0 Million in Restric

PRINCETON, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoSorbents Corporation ( CTSO), a leader in the treatment of life-threatening conditions in the intensive

Critical care company CytoSorbents Corp. (CTSO) announced Friday preliminary fourth-quarter results, expecting 22 percent to 25 percent growth in product revenue, while product gross margin would be lower.

CytoSorbents reports revenue growth in Q4

Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70%